Change in patient-reported and systemic disease activity and IgG levels after vaccination for all patients with pSS
| Total pSS group | Baseline | After vaccination | P value |
| Total ESSPRI | 6.0 (4.7–7.0) (n=67) | 5.7 (3.8–7.0) (n=64) | 0.16 |
| ESSPRI—dryness | 7.0 (5.0–8.0) (n=67) | 6.0 (4.0–7.0) (n=66) | 0.053 |
| ESSPRI—fatigue | 6.0 (5.0–8.0) (n=67) | 7.0 (4.0–7.0) (n=65) | 0.64 |
| ESSPRI—pain | 6.0 (4.0–7.0) (n=67) | 5.0 (3.0–7.0) (n=65) | 0.17 |
| Patient GDA | 6.0 (5.0–7.0) (n=67) | 6.0 (4.0–7.0) (n=66) | 0.20 |
| ESSDAI | 3.0 (1.0–4.0) (n=59) | 2.0 (0.3–4.8) (n=36) | 0.88 |
| IgG | 13.0 (10.3–18.5) (n=63) | 12.6 (9.8–18.3) (n=63) | 0.26 |
Data presented as median (IQR).
Baseline ESSDAI was collected within 1 year before the first vaccination (median time 4 months) and follow-up ESSDAI was collected within 6 months after vaccination.
ESSPRI, patient GDA and IgG scores were collected at baseline and 28 days after the second vaccination (first for Janssen).
ESSDAI, EULAR Sjögren’s Syndrome Disease Activity Index; ESSPRI, EULAR Sjögren’s Syndrome Patient Reported Index; GDA, global disease activity; pSS, primary Sjögren’s syndrome.